No photo of Jessica K Altman

View Scopus Profile

Jessica K Altman

  • 3692 Citations
20052024
If you made any changes in Pure, your changes will be visible here soon.

Personal profile

Certifications and Licenses

Medical Oncology
Internal Medicine
Hematology

Training Experience

2004Residency, University of Chicago Hospitals
2007Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital)

Education/Academic qualification

MD, University of Pittsburgh

… → 2001

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 32 Similar Profiles
Acute Myeloid Leukemia Medicine & Life Sciences
Acute Promyelocytic Leukemia Medicine & Life Sciences
Sirolimus Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Tretinoin Medicine & Life Sciences
Phosphotransferases Medicine & Life Sciences
Cytarabine Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2007 2024

Targeting Novel Protein Complexes for the Treatment of Acute Myeloid Leukemia

Altman, J. K., Beauchamp, E. M., Eklund, E. A. & Platanias, L. C.

National Cancer Institute

6/1/19 → 5/31/24

Project: Research project

Cyclin-Dependent Kinase 9
Protein Transport
Acute Myeloid Leukemia
Protein Biosynthesis
Heterografts

Prot #2215-CL-1101: Phase 1/2 Study of ASP2215 (Gilteritinib) Combined with Atezolizumab in Patients with Relapsed or Treatment Refractory FLT3 Mutated Acute Myeloid Leukemia (AML)

Altman, J. K.

Syneos Health, Inc., Astellas Pharma Global Development, Inc.

4/23/19 → 4/23/22

Project: Research project

Prot #M16-802: A Multicenter, Open-Label Phase 1b Study to Assess Safety and Efficacy of Venetoclax in Combination with Gilteritinib in Subjects with Relapsed/Refractory Acute Myeloid Leukemia.

Altman, J. K.

AbbVie Inc.

2/27/19 → 2/27/20

Project: Research project

Prot #AMV564-101: A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Altman, J. K.

Amphivena Therapeutics, Inc.

10/18/18 → 10/18/21

Project: Research project

Prot #FF-10101-US101/201: A First-in-Human Phase 1/2a Study to Assess the Safety, Tolerability, Efficacy, and Pharmacokinetics of FF-10101-01 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

Altman, J. K.

Quintiles, Inc., FUJIFILM Pharmaceuticals U.S.A., Inc.

8/2/17 → 8/2/20

Project: Research project

Research Output 2005 2019

2 Citations (Scopus)

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease

Litzow, M. R., Wang, X. V., Carroll, M. P., Karp, J. E., Ketterling, R. P., Zhang, Y., Kaufmann, S. H., Lazarus, H. M., Luger, S. M., Paietta, E. M., Pratz, K. W., Tun, H. W., Altman, J. K., Broun, E. R., Rybka, W. B., Rowe, J. M. & Tallman, M. S., Jan 1 2019, In : American Journal of Hematology. 94, 1, p. 111-117 7 p.

Research output: Contribution to journal › Article

alvocidib
Mitoxantrone
Cytarabine
Acute Myeloid Leukemia
Topotecan
1 Citation (Scopus)

Identification and targeting of novel CDK9 complexes in acute myeloid leukemia

Beauchamp, E. M., Abedin, S. M., Radecki, S. G., Fischietti, M., Arslan, A. D., Blyth, G. T., Yang, A., Lantz, C., Nelson, A., Goo, Y. A., Akpan, I., Eklund, E. A., Frankfurt, O., Fish, E. N., Thomas, P. M., Altman, J. K. & Platanias, L. C., Mar 14 2019, In : Blood. 133, 11, p. 1171-1185 15 p.

Research output: Contribution to journal › Article

Cyclin-Dependent Kinase 9
Sirolimus
Acute Myeloid Leukemia
Cytoplasm
Chemical activation
7 Citations (Scopus)

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Stein, E. M., DiNardo, C. D., Fathi, A. T., Pollyea, D. A., Stone, R. M., Altman, J. K., Roboz, G. J., Patel, M. R., Collins, R., Flinn, I. W., Sekeres, M. A., Stein, A. S., Kantarjian, H. M., Levine, R. L., Vyas, P., MacBeth, K. J., Tosolini, A., VanOostendorp, J., Xu, Q., Gupta, I. & 7 othersLila, T., Risueno, A., Yen, K. E., Wu, B., Attar, E. C., Tallman, M. S. & de Botton, S., Feb 14 2019, In : Blood. 133, 7, p. 676-687 12 p.

Research output: Contribution to journal › Article

Open Access
Isocitrate Dehydrogenase
Acute Myeloid Leukemia
Refractory materials
Mutation
Transplants

Rare myeloid sarcoma with KMT2A (MLL)-ELL fusion presenting as a vaginal wall mass

Bao, H., Gao, J., Chen, Y-H., Altman, J. K., Frankfurt, O., Wilson, A. L., Sukhanova, M., Chen, Q. C. & Lu, X., Mar 28 2019, In : Diagnostic pathology. 14, 1, 26.

Research output: Contribution to journal › Article

Open Access
Myeloid Sarcoma
Histiocytic Sarcoma
Uterine Hemorrhage
Neoplasms
Chromosomes, Human, Pair 18
10 Citations (Scopus)

A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

Levis, M. J., Perl, A. E., Altman, J. K., Gocke, C. D., Bahceci, E., Hill, J., Liu, C., Xie, Z., Carson, A. R., McClain, V., Stenzel, T. T. & Miller, J. E., Apr 24 2018, In : Blood advances. 2, 8, p. 825-831 7 p.

Research output: Contribution to journal › Article

Residual Neoplasm
Acute Myeloid Leukemia
Mutation
DNA
fms-Like Tyrosine Kinase 3